The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model

Cancer Immunology, Immunotherapy

Volumn 60, Issue 5, 2011, Pages 609-619

  Tadmor, Tamar ^a   Zhang, Yu ^c   Cho, Hyun Mi ^c   Podack, Eckhard R ^b   Rosenblatt, Joseph D ^b,c  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Anti tumor immunity; B lymphocyte; B cell deficient mice (BCDM); Immune competent mice (ICM); T regulatory cells (T reg)

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BREAST ADENOCARCINOMA; BREAST TUMOR; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 79955539126     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0972-z     Document Type: Article

References (39)

1. LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112(5):1570-1580
2. Shah S, Divekar AA, Hilchey SP et al (2005) Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells Int J Cancer 117(4):574-586
3. Inoue S, Leitner W, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66:7741-7747 (Pubitemid 44289234)
4. Brodt P, Gordon J (1978) Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J Immunol. 121(1):359-62 (Pubitemid 8384890)
5. G Zhou HI Levitsky 2007 Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance J Immunol 178 2155 2162 17277120 1:CAS:528:DC%2BD2sXht1Cgu74%3D (Pubitemid 46233413)
6. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108(3):804-811 (Pubitemid 44154611)
7. P Reichardt B Dornbach S Rong, et al. 2007 Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse Blood 110 1519 1529 17392507 10.1182/blood-2006-10-053793 1:CAS:528:DC%2BD2sXhtVSgsb3J No. 5 (Pubitemid 47443968)
8. + CD4 T cells. J Immunol 179:2046-2050
9. RS Bystry V Aluvihare KA Welch M Kallikourdis AG Betz 2001 B cells, professional APCs recruit regulatory T cells via CCL4 Nat Immunol 2 12 1126 1132 11702067 10.1038/ni735 1:CAS:528:DC%2BD3MXptVaitrk%3D (Pubitemid 33130146)
10. Knoechel B, Lohr J, Kahn E, Abbas AK (2005) The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J Immunol 175(1):21-26 (Pubitemid 40884296)
11. Levings MK, Sangregorio R, Roncarolo MG (2001) Human Cd25+ Cd4+ T Regulatory cells suppress naive and memory T Cell Proliferation and can be expanded in vitro without loss of function. J Exp Med 193:1295-1302
12. F Baratelli Y Lin L Zhu, et al. 2005 Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells J Immunol 175 1483 1490 16034085 1:CAS:528:DC%2BD2MXmtlWjtrc%3D (Pubitemid 41023048)
13. + T regulatory cells J Immunol 176 3301 3305 16517695 1:CAS:528:DC%2BD28XitVSksLw%3D (Pubitemid 43363974)
14. + Regulatory T Cells Following Anti-CD25 Treatment in Malaria-Infected Mice J Immunol 178 4136 4146 17371969 1:CAS:528:DC%2BD2sXjt1Wltb8%3D (Pubitemid 46492363)
15. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59(13):3128-3133 (Pubitemid 29316012)
16. GS Nabors T Nolan W Croop J Li JP Farrell 1995 The influence of the site of parasite inoculation on the development of Th1 and Th2 type immune responses in (BALB/c x C57BL/6) F1 mice infected with Leishmania major Parasite Immunol 17 11 569 579 8817603 10.1111/j.1365-3024.1995.tb01000.x 1:STN:280: DyaK28vhsVGrsA%3D%3D (Pubitemid 26005619)
17. Chen X, Oppenheim JJ, Howard OM (2005) BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol 78(1):114-121. (Epub 2005 Apr 21) (Pubitemid 40979950)
18. Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res 66(8):4488-4495
19. Z Qin G Richter T Schüler S Ibe X Cao T Blankenstein 1998 B cells inhibit induction of T cell-dependent tumor immunity Nat Med 4 5 627 630 9585241 10.1038/nm0598-627 1:CAS:528:DyaK1cXjtFKgtrY%3D (Pubitemid 28237366)
20. Mizoguchi A, Bhan AK (2006) A case for regulatory B cells. J Immunol 176: 705-710 (Pubitemid 43099663)
21. + phenotype controls T cell-dependent inflammatory responses. JI 28(5);639-650 (Pubitemid 351636247)
22. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF (2009) The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 182(12):7459-7472
23. S Lemoine A Morva P Youinou C Jamin 2009 Regulatory B cells in autoimmune diseases: how do they work? Ann N Y Acad Sci 1173 260 267 19758160 10.1111/j.1749-6632.2009.04651.x 1:CAS:528:DC%2BD1MXhtlCntrzN
24. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of Regulatory T Cells in the Peripheral Blood of Cancer Patients. Clin Cancer Res 9:606-612 (Pubitemid 36182591)
25. Kretschmer K, Apostolou I, Jaeckel E, Khazaie K, von Boehmer H (2006) Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev 212:163-169 (Review) (Pubitemid 44116707)
26. AJ Rech RH Vonderheide 2009 Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells Ann N Y Acad Sci 1174 99 106 19769742 10.1111/j.1749-6632. 2009.04939.x 1:CAS:528:DC%2BD1MXhtlehs7vL
27. Kim S, Fridlender ZG, Dunn R et al (2008) B cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models J Immunother 31(5):446-457
28. Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, Demengeot J (2005) Foxp3+CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci USA 102(11):4091-4096. (Epub 2005 Mar 7) (Pubitemid 40388560)
29. A Suto H Nakajima K Ikeda, et al. 2002 CD4+CD25+ T-cell development is regulated by at least 2 distinct mechanisms Blood 99 555 560 11781238 10.1182/blood.V99.2.555 1:CAS:528:DC%2BD38XmslGksA%3D%3D No. 2 (Pubitemid 34533092)
30. Molina A (2008) A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 59:237-250. (Review) (Pubitemid 351291630)
31. Mease PJ (2008) B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 35(7):1245-1255. (Review) (Pubitemid 352000767)
32. TM Brusko CH Wasserfall MJ Clare-Salzler DA Schatz MA Atkinson 2005 Functional defects, the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes Diabetes 54 5 1407 1414 15855327 10.2337/diabetes.54.5.1407 1:CAS:528:DC%2BD2MXktVCksL0%3D (Pubitemid 40586671)
33. J Chen A Schmidtt K Ginnopoulos, et al. 2007 Imatinib impairs the proliferation and function of CD4+CD25+ regulatory T cells in a dose-dependent manner Int J Oncol 31 1133 1139 17912440 1:CAS:528:DC%2BD2sXhtlKhsrfK
34. Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with Rituximab Blood 112(4):1147-1150. (Epub 2008 Mar 28)
35. Stasi R, Del Poeta G, Stipa E et al (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110(8):2924-2930 (Pubitemid 350006946)
36. Chapoval AI, Fuller JA, Kremlev SG, Kamdar SJ, Evans R (1998) Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol 161(12):6977-6984 (Pubitemid 28562246)
37. Perricone MA, Smith KA, Claussen KA et al (2004) Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother 27(4):273-281 (Pubitemid 38833323)
38. Aklilu M, Stadler WM, Markiewicz M et al (2004) Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann Oncol 15(7):1109-1114 (Pubitemid 39099116)
39. Barbera-Guillem E, Nelson MB, Barr B et al (2000) B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 48(10):541-549 (Pubitemid 30004488)